314 related articles for article (PubMed ID: 17363490)
1. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Mimeault M; Moore E; Moniaux N; Hénichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2006 Feb; 118(4):1022-31. PubMed ID: 16108016
[TBL] [Abstract][Full Text] [Related]
3. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Mimeault M; Venkatraman G; Johansson SL; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
Int J Cancer; 2007 Jan; 120(1):160-9. PubMed ID: 17013895
[TBL] [Abstract][Full Text] [Related]
4. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Mimeault M; Mehta PP; Hauke R; Henichart JP; Depreux P; Lin MF; Batra SK
Growth Factors; 2007 Dec; 25(6):400-16. PubMed ID: 18365871
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Mimeault M; Johansson SL; Henichart JP; Depreux P; Batra SK
Mol Cancer Ther; 2010 Mar; 9(3):617-30. PubMed ID: 20179163
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Lin J; Wu H; Shi H; Pan W; Yu H; Zhu J
PLoS One; 2013; 8(10):e76169. PubMed ID: 24155892
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Lin JZ; Hameed I; Xu Z; Yu Y; Ren ZY; Zhu JG
Oncol Rep; 2018 Oct; 40(4):2242-2250. PubMed ID: 30066906
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
Mimeault M; Pommery N; Hénichart JP
Int J Cancer; 2003 Aug; 106(1):116-24. PubMed ID: 12794766
[TBL] [Abstract][Full Text] [Related]
11. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells.
Hu WG; Liu T; Xiong JX; Wang CY
Acta Pharmacol Sin; 2007 Aug; 28(8):1224-30. PubMed ID: 17640486
[TBL] [Abstract][Full Text] [Related]
12. An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Salzberg M; Rochlitz C; Morant R; Thalmann G; Pedrazzini A; Roggero E; Schönenberger A; Knuth A; Borner M
Onkologie; 2007 Jul; 30(7):355-60. PubMed ID: 17596743
[TBL] [Abstract][Full Text] [Related]
13. Carnosol inhibits Hedgehog signaling pathway in both LNCaP and DU145 prostate cancer cell lines.
Gao H; Song Q; Yang J; Yu S; Zhao J; Yu G
Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):104-108. PubMed ID: 28886322
[TBL] [Abstract][Full Text] [Related]
14. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway.
Datta MW; Hernandez AM; Schlicht MJ; Kahler AJ; DeGueme AM; Dhir R; Shah RB; Farach-Carson C; Barrett A; Datta S
Mol Cancer; 2006 Mar; 5():9. PubMed ID: 16507112
[TBL] [Abstract][Full Text] [Related]
15. Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Festuccia C; Gravina GL; Angelucci A; Millimaggi D; Muzi P; Vicentini C; Bologna M
Int J Cancer; 2005 Jul; 115(4):630-40. PubMed ID: 15700310
[TBL] [Abstract][Full Text] [Related]
16. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
[TBL] [Abstract][Full Text] [Related]
17. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K
Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379
[TBL] [Abstract][Full Text] [Related]
18. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer.
Yamamichi F; Shigemura K; Behnsawy HM; Meligy FY; Huang WC; Li X; Yamanaka K; Hanioka K; Miyake H; Tanaka K; Kawabata M; Shirakawa T; Fujisawa M
Scand J Urol; 2014 Dec; 48(6):523-32. PubMed ID: 25356787
[TBL] [Abstract][Full Text] [Related]
19. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling.
Ibuki N; Ghaffari M; Pandey M; Iu I; Fazli L; Kashiwagi M; Tojo H; Nakanishi O; Gleave ME; Cox ME
Int J Cancer; 2013 Oct; 133(8):1955-66. PubMed ID: 23564295
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Corkery B; Crown J; Clynes M; O'Donovan N
Ann Oncol; 2009 May; 20(5):862-7. PubMed ID: 19150933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
